Drug‐Induced Gynecomastia

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Volumn 13, Issue 1, 1993, Pages 37-45

  Thompson, Dennis F ^a   Carter, Jayne Reading ^b  

^a SOUTHWESTERN OKLAHOMA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CANNABIS; CHLORMETHINE; CHORIONIC GONADOTROPIN; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DIGITALIS; DIGOXIN; DILTIAZEM; DOXORUBICIN; FOLLITROPIN; HISTAMINE H2 RECEPTOR ANTAGONIST; KETOCONAZOLE; LUTEINIZING HORMONE; NEUROLEPTIC AGENT; NIFEDIPINE; PHENOTHIAZINE; PREDNISONE; PROCARBAZINE; PROLACTIN; SPIRONOLACTONE; VERAPAMIL; VINBLASTINE;

CANCER; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; DRUG RECHALLENGE; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; GYNECOMASTIA; HUMAN; HYPERTENSION; LUTEINIZING HORMONE BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; REVIEW; TESTOSTERONE BLOOD LEVEL; ULCER; ZOLLINGER ELLISON SYNDROME;

ANTINEOPLASTIC AGENTS; ANTIPSYCHOTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CANNABIS; GYNECOMASTIA; HISTAMINE H2 ANTAGONISTS; HUMAN; KETOCONAZOLE; MALE; SPIRONOLACTONE;

EID: 0027536325     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/j.1875-9114.1993.tb02688.x     Document Type: Review

References (86)

1. Gynecomastia as a physical finding in normal men
2. Gynecomastia in a hospitalized male population
3. Endocrine disorders of the breast
4. Gynecomastia. A continuing diagnostic dilemma [editorial]
5. Gynecomastia
6. Gynecomastia associated with calcium channel blocker therapy
7. Unilateral gynecomastia and nifedipine
8. Effects of five days verapamil administration on serum GH and PRL levels
9. Hyperprolactinemia‐galactorrhea induced by verapamil
10. Verapamil‐induced hyperprolactinemia and galactorrhea
11. Chemotherapy, testicular damage, and gynecomastia: an endocrine “black hole.”
12. Gynecomastia in men following antineoplastic therapy
13. Gynecomastia and gonadal dysfunction in adolescent boys treated with combination chemotherapy for Hodgkin's disease
14. Gynecomastia after cytotoxic therapy for metastatic testicular cancer
15. Painful gynecomastia following cytotoxic therapy for testis cancer: a potentially favorable prognostic sign?
16. Gynecomastia after chemotherapy for lymphoma
17. Gynecomastia complicating the treatment of myeloma
18. Gynecomastia with nitrosourea therapy
19. Gynecomastia associated with vincristine therapy
20. Leydig cell dysfunction and gynecomastia in adult males treated with alkylating agents
21. Gynecomastia during digitalis therapy. Report of eight additional cases with liver function studies
22. Gynecomastia during digitalis therapy
23. Digitalis intoxication in elderly patients
24. Gynecomastia following digitalis administration
25. Effect of digitalis on urinary pituitary gonadotropin excretion
26. Digoxin and abnormal serum hormone levels
27. Gynecomastia and histamine‐2 antagonists
28. Breast changes in males on cimetidine
29. Breast tumor and polymyositis following cimetidine therapy—a possible association
30. Cimetidine blocks testosterone synthesis
31. Effect of cimetidine on gonadal function in man
32. Gynecomastia associated with cimetidine
33. Cimetidine‐induced impotence and breast changes in patients with gastric hypersecretory states
34. Prolactin and the hypothalamic‐pituitary‐testicular axis in cimetidine‐treated men
35. Gynecomastia with cimetidine
36. Painful gynecomastia with cimetidine
37. Gynecomastia during omeprazole therapy
38. Prolactin responses to neuroleptics in normal and schizophrenic subjects
39. The effect of neuroleptics on serum prolactin in schizophrenic patients
40. Serum prolactin levels in patients with gynecomastia
41. Gynecomastia during phenothiazine therapy
42. Endocrine effects of psychotropic drugs. I. Galactorrhea and gynecomastia
43. Clozapine as an alternative treatment for neuroleptic‐induced gynecomastia
44. Gynecomastia with ketoconazole
45. Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins
46. Ketoconazole‐induced drop in serum and saliva testosterone
47. Ketoconazole blocks testosterone synthesis
48. High‐dose ketoconazole therapy and adrenal and testicular function in humans
49. Ketoconazole‐induced increase in estradiol‐testosterone ratio
50. Gynecomastia in marijuana users
51. Depression of plasma testosterone levels after chronic intensive marijuana use
52. Plasma testosterone levels before, during and after chronic marijuana smoking
53. Spurious rise in human chorionic gonadotropin induced by marijuana in patients with testicular cancer
54. Hyperprolactinaemia in patients with suspected cannabis‐induced gynecomastia
55. Long‐term experience of spironolactone in essential hypertension
56. Adverse reactions to spironolactone: a report from the Boston collaborative drug surveillance program
57. Unilateral gynecomastia and impotence during low‐dose spironolactone administration in men
58. Gynecomastia induced in normal males by spironolactone
59. Gynecomastia and semen abnormalities induced by spironolactone in normal men
60. Gynaecomastia after spironolactone and potassium canrenoate
61. Anti‐androgenic activity of spironolactone
62. Pathophysiology of spironolactone‐induced gynecomastia
63. Increased serum oestrone and oestradiol following spironolactone administration in hypertensive men
64. Spironolactone and endocrine dysfunction
65. Spironolactone metabolism and gynaecomastia [letter]
66. Spironolactone and potassium canrenoate metabolism
67. Gynecomastia as a complication of auranofin therapy
68. Reversible gynaecomastia associated with etretinate
69. Amiodarone‐induced gynecomastia
70. Gynaecomastia associated with captopril
71. A controlled trial of metoclopramide in symptomatic gastroesophageal reflux
72. Increased oestradiol in diazepam‐related gynaecomastia
73. Gynaecomastia and diazepam abuse
74. Gynaecomastia in a male infant given domperidone
75. Gynaecomastia after long‐term administration of domperidone
76. Gynecomastia associated with theophylline
77. Reversible gynecomastia associated with sulindac therapy
78. Metronidazole‐induced gynecomastia
79. Gynaecomastia induced by phenytoin in men with epilepsy
80. Gynecomastia associated with low‐dose methotrexate therapy
81. Reversible gynaecomastia associated with d‐penicillamine in a man with rheumatoid arthritis
82. Methadone‐associated gynecomastia
83. Pseudogynecomastia due to penicillin adjuvant
84. Gynecomastia in association with administration of thiacetazone in the treatment of tuberculosis
85. Gynecomastia during omeprazole therapy
86. The pathogenesis of gynecomastia